Business
Completion of Dosing Phase of Canine Gene Therapy
Genflow Biosciences Plc has successfully completed the dosing phase of its canine gene therapy trial for its investigational SIRT6-based therapy, reporting no adverse events during administration, which demonstrates a strong safety and tolerability profile. The company anticipates a first efficacy read in mid-to-late January 2026, with a second assessment planned for June-July 2026, after which Genflow intends to resume discussions regarding potential early-stage licensing opportunities with animal health companies. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \n \nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n \nGenflow Biosciences Plc\n \n \nGenflow Completes Dosing Phase of Canine Gene Therapy Trial\nNo Adverse Events Reported During Administration\n \nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company's investigational SIRT6-based gene therapy.\n \nImportantly, no adverse events were reported during the dosing phase of the study. No serious, moderate, or minor side effects were observed, demonstrating a strong safety and tolerability profile for the therapy.\n \nThe study is being conducted as a blinded clinical trial and, as such, efficacy outcomes cannot yet be assessed. Genflow expects a first efficacy read in mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate potential therapeutic benefits related to sarcopenia, overall healthspan, and lifespan-associated biomarkers.\n \nThe dogs enrolled in the trial will continue to be monitored for a total duration of 180 days. A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate durability and longer-term effects of the gene therapy.\n \nFollowing analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies, including parties currently engaged under confidentiality and data access agreements, to explore potential early-stage licensing opportunities.\n \nDr. Eric Leire, CEO of Genflow, commented: \"These milestones represent an important step forward for our longevity program. The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach. We look forward t...